Ultra-deep sequencing of thousands of tumor barcodes unique to each individual tumor revealed that daily treatment with RMC-6236 drove significant and consistent reductions in tumor burden (median number of neoplastic tumor cells in RMC-6236–treated mice relative to vehicle-treated mice) across all oncogenic Kras variants tested (Fig. 4A). The gene discussed is KRAS; the disease is neoplasm.